Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor ...

Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...

SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental ...

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib. Falk G. Bechara, MD, discusses long-term tunnel ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed randomized trial in hidradenitis suppurativa at Fall Clinical 2026. At Fall ...

Dr. Singh presents a 76-year-old woman with a 6-year history of recurrent basal cell carcinoma involving the nasal sidewall ...

A young construction worker managed with photoprotection alone continues to have breakthrough phototoxicity and mildly ...

The American Academy of Dermatology (AAD) and Hidradenitis Suppurativa Foundation (HSF) have issued their first joint ...

Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, ...

Skin longevity is on a path to becoming a legitimate and consequential area of dermatology. For it to fully succeed, skin ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...

This episode, "Efficacy and Safety Data for Emerging Oral HS Agents," has Chao presenting the latest trial results for ...